Welcome to My Personal Page
Support My Ride to Conquer Cancer®
This August I will be participating in the Ride to Conquer Cancer – a 2 day, 250km ride from Vancouver to Seattle – on the Daryl’s Heidelberg Hope team.
Daryl Clark, a close family friend for as long as I can remember, passed away on June 17, 2017. He had a goal of bringing an end to cancer. He wanted to introduce an emerging treatment out of Germany for aggressive prostate cancer into the North American market. As a member of the Daryl’s Heidelberg Hope team, we ride for Daryl and set out to achieve his goal.
This new treatment has had tremendous efficacy rates. 75% of metastasized prostate patients who were given two to four months to live were not only alive six months after receiving the treatment, but their tumors had shrunk and they had lower levels of PSMA in their blood.
The treatment is a radiopharmaceutical that is injected by IV. The IV is loaded with a radioactive element (Lutetium) that has been chemically bound to a certain antibody. This combination, upon injection, circulates throughout the body attaching itself to cancer cells and killing them. Perhaps most encouraging, this treatment kills cancer cells wherever they reside – the bones, lymph nodes, soft tissue organs or simply in the bloodstream. It was Daryl's dream that this new treatment be made available in BC for all cancer patients.
Our team met with Sarah Roth, CEO of the BC Cancer Foundation and Dr. Francois Benard, head of Research at the BC Cancer Agency a number of times over the past six months. We have their full commitment (this will be a collaboration with BCCA, VGH and UBC), a defined budget (approx. $4.5mm) with deliverables and a timeline. The intent is to start two clinical trials towards the end of the year.
- All proceeds will go directly to fund the two very specific clinical trials; and
- 100% of your funds will go to this research – no administrative costs will come off the top.
If you choose to support the cause, which I sincerely hope you do, please donate.
Thank you for your time,
If you think this page contains objectionable content, please inform the system administrator.